Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy

Journal of NeuroVirology

Volumn 21, Issue 6, 2015, Pages 637-644

  Dong Si, Tuan ^a   Gheuens, Sarah ^a   Gangadharan, Amy ^a   Wenten, Made ^a   Philip, Jeffrey ^a   McIninch, James ^a   Datta, Shoibal ^a   Richert, Nancy ^a   Bozic, Carmen ^a   Bloomgren, Gary ^a   Richman, Sandra ^a   Weber, Thomas ^b   Clifford, David B ^c  

^a BIOGEN   (United States)

^b UNIVERSITY OF HAMBURG   (Germany)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Expanded Disability Status Scale; Karnofsky Performance Scale; Natalizumab; Progressive multifocal leukoencephalopathy; Survival

Indexed keywords

NATALIZUMAB; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SCORING SYSTEM; STRUCTURED QUESTIONNAIRE; SURVIVAL; SURVIVOR; VIRUS LOAD; BRAIN; CHEMICALLY INDUCED; JC VIRUS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; STATISTICS AND NUMERICAL DATA; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BRAIN; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; JC VIRUS; KAPLAN-MEIER ESTIMATE; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NATALIZUMAB; SURVIVORS; VIRAL LOAD; YOUNG ADULT;

EID: 84946471286     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-015-0316-4     Document Type: Article

References (30)

1. Amato MP, Portaccio E (2007) Clinical outcome measures in multiple sclerosis. J Neurol Sci 259:118–122
2. Antoniol C, Jilek S, Schluep M et al (2012) Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology 79:2258–2264
3. Belachew S, Phan-Ba R, Bartholomé E et al (2011) Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 18:240–245
4. Bloomgren G, Richman S, Hotermans C et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870–1880
5. Casado JL, Corral I, García J et al (2013) Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis 33:179–187
6. Cleveland WS (1981) LOWESS: a program for smoothing scatterplots by robust locally weighted regression. Am Stat 35:54
7. De Luca A, Ammassari A, Cingolani A, Giancola ML, Antinori A (1998) Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretroviral therapy. AIDS 12:1937–1938
8. Delbue S, Elia F, Carloni C et al (2012) JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy. J Cell Physiol 227:3511–3517
9. Dong-Si T, Richman S, Wattjes MP et al (2014) Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Translational Neurol 1:755–764
10. Dong-Si T, Weber T, Richert N et al (2012) Classification of natalizumab case reports with progressive multifocal leukoencephalopathy [abstract]. Neurology 78(Suppl 1):P07.058
11. Fanjul F, Riveiro-Barciela M, Gonzalez J et al (2013) Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score? HIV Med 14:321–325
12. Gasnault J, Costagliola D, Hendel-Chavez H et al (2011) Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One 6:e20967
13. Gheuens S, Bord E, Kesari S et al (2011) Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 85:7256–7263
14. Gheuens S, Wüthrich C, Koralnik IJ (2013) Progressive multifocal leukoencephalopathy: why gray and white matter. Annu Rev Pathol 8:189–215
15. Giacomini PS, Rozenberg A, Metz I et al (2014) Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 370:486–488
16. Hall CD, Dafni U, Simpson D et al (1998) Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 338:1345–1351
17. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457–481
18. Karnofsky D, Burchenal J (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLoad CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 191–205
19. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
20. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375–381
21. Lima MA, Bernal-Cano F, Clifford DB, Gandhi RT, Koralnik IJ (2010) Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry 81:1288–1291
22. Marzocchetti A, Tompkins T, Clifford DB et al (2009) Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 73:1551–1558
23. Mateen FJ, Muralidharan R, Carone M et al (2011) Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 70:305–322
24. Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910
25. Post MJ, Yiannoutsos C, Simpson D et al (1999) Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol 20:1896–1906
26. R Development Core Team (2014) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: www.R-project.org. Accessed December 9, 2014
27. Rudick RA (2011) Multiple sclerosis, natalizumab, and PML: helping patients decide. Cleve Clin J Med 78(Suppl 2):S18–S231
28. Therneau T (2013) A package for survival analysis in S. R package version 2.37-4. Available at: http://CRAN.R-project.org/package=survival. Accessed December 9, 2014
29. Vermersch P, Kappos L, Gold R et al (2011) Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76:1697–1704
30. Yiannoutsos CT, Major EO, Curfman B et al (1999) Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 45:816–821